www.signsofsma.com Open in urlscan Pro
52.17.126.66 Public Scan

Back to summary

Submitted URL:
http://www.signsofsma.ch/
Effective URL:
https://www.signsofsma.com/hcp-what-is-spinal-muscular-atrophy
Submission: On July 08 via manual (July 8th 2024, 2:28:52 pm UTC) from DE — Scanned from CH

Form analysis
0 forms found in the DOM

Text Content

This site is intended for a global Health Care Professional (HCP) audience only

Go to Caregiver site |
Select a country or region
* Argentina (Español)
* Croatia (Hrvatski)
* Czechia (čeština)
* France (Francais)
* Global (English)
* Hungary (Magyar)
* Ireland (English)
* Italy (Italiano)
* Poland (Polski)
* Portugal (Português)
* Romania (Română)
* Russia (русский)
* Saudi Arabia (عربي)
* Spain (Español)

* * WHAT IS SMA
* WHAT IS SMA
* CAUSE OF SMA
* STOPPING NEURONAL LOSS
* IMPORTANCE OF EARLY DIAGNOSIS
WHAT IS SMA(current)
* * THE SIGNS OF SMA
* THE SIGNS OF SMA
* DOWNLOAD THE SMA SIGNS WATCHLIST
* INFANTILE NMD
* DOWNLOAD THE DIFFERENTIAL DIAGNOSIS OVERVIEW
THE SIGNS OF SMA
* * REFER FOR DIAGNOSIS
* REFER FOR DIAGNOSIS
* CONTINUAL CLINICAL VIGILANCE
REFER FOR DIAGNOSIS
* FAQ
* * NEWS AND INFO
* NEWS
* SMA COMMUNITY
NEWS AND INFO

Select country or region
* Argentina (Español)
* Croatia (Hrvatski)
* Czechia (čeština)
* France (Francais)
* Global (English)
* Hungary (Magyar)
* Ireland (English)
* Italy (Italiano)
* Poland (Polski)
* Portugal (Português)
* Romania (Română)
* Russia (русский)
* Saudi Arabia (عربي)
* Spain (Español)

Go to Caregiver site >

LOOK OUT FOR EARLY WARNING SIGNS OF SPINAL MUSCULAR ATROPHY (SMA)1–3

REFER FOR DIAGNOSIS

For babies with SMA fast diagnosis is vital. This is because any lower motor
neuron damage occurring before treatment is irreversible4,5

WHAT IS SMA?

SMA is a rare, progressive, inherited monogenic disease, characterized by lower
motor neuron degeneration and muscle weakness6–10

Untreated, SMA is the 2nd most common fatal autosomal recessive disorder after
cystic fibrosis11

SMA remains the leading genetic cause of infant mortality in the absence of
therapeutic intervention5,10

SMA is typically classified into 4 phenotypes (Types 1–4) that range in
severity. SMA Types 1 and 2 are the most severe and common forms with onset
between birth and 18 months3,5,10

SMA affects approximately 1 in 10,000 – 12,000 live births and can impact any
race or sex6,12

Around 1 in 50 people are carriers of the disease mutation13

CAUSE OF SMA

SMA is caused by an absent or dysfunctional survival motor neuron 1 (SMN1)
gene14–18

The body has a back-up gene, SMN2, however, it is only capable of producing a
small amount of functional SMN protein, which is insufficient for motor neuron
survival and function6,14,15,17,18

Click to see the difference:

* Unaffected individual
* Affected individual

UNAFFECTED INDIVIDUAL:

* SMN protein is critical for neuronal survival and neuromuscular junction
formation15

* SMN1 is the primary gene that encodes SMN protein with SMN2 as a back-up15,19

Functional SMN protein

Non-functional SMN protein

Video Player is loading.

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque
Font Size50%75%100%125%150%175%200%300%400%Text Edge
StyleNoneRaisedDepressedUniformDropshadowFont FamilyProportional
Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall
Caps
Reset restore all settings to the default valuesDone
Close Modal Dialog

End of dialog window.

Functional SMN protein

Non-functional SMN protein

AFFECTED INDIVIDUAL:

* SMN1 gene is absent or dysfunctional14–17

* SMN2 alone is unable to produce sufficient SMN protein6,14,15,18

* SMN protein deficiency leads to irreversible neuronal degeneration and loss
of muscle function in SMA5,14,15

Functional SMN protein

Non-functional SMN protein

Video Player is loading.

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

End of dialog window.

Functional SMN protein

Non-functional SMN protein

STOPPING NEURONAL LOSS

Loss of motor neurons in SMA is irreversible4,5

* Age 0–6 months
* Age 6–18 months

DISEASE PROGRESSION

More than 90% of untreated patients with SMA Type 1 will not survive or will
need permanent ventilatory support by 2 years of age20

Every delay in the diagnosis of SMA Type 1 can jeopardize lower motor neuron
survival,4 directly impacting neuromuscular function21

Your rapid referral is crucial to halt or delay disease progression, and enable
your patient access to the best available care4,10,22

PNCR: SMA Type 1 survival rates*

NeuroNext: SMA Type 1 survival rates*

PNCR, Pediatric Neuromuscular Clinical Research

*Event-free survival for PNCR = no death, and no need for ≥16 hours/day
ventilation continuously for 14 days, in the absence of an acute reversible
illness;20 n=23 (Type 1 patients with 2 copies of SMN2). Survival for NeuroNext
= no death, or no intubation; n=2021

Adapted from Anderton RS and Mastaglia FL. 201515, Finkel RS. 201324, Finkel RS,
et al. 201420 and Kolb SJ, et al. 201721

DISEASE PROGRESSION

While patients diagnosed with SMA Type 2 (with disease onset between 6–18 months
of age) may possibly reach motor milestones in the first years of life, all
patients will show a clear and progressive decline with long-term follow-up8

Every delay in the diagnosis of SMA can jeopardize lower motor neuron survival,4
directly impacting neuromuscular function4,10,22

Your rapid referral is crucial to halt or delay disease progression, and enable
your patient access to the best available care4,10,22

TIMPSI: Average Test of Infant Motor Performance Screening Items

Adapted from Kolb SJ, et al. 201721

IMPORTANCE OF EARLY DIAGNOSIS

Fast diagnosis of SMA is vital, as damage that occurs before treatment is
irreversible4,5

EARLY DIAGNOSIS OF SMA IS CRITICAL TO:25–27

* Begin optimal therapeutic intervention and management strategies

* Relieve the stress and burden experienced by patients and caregivers

Research suggests early medical intervention provides the most benefit in
SMA10,22,28

Adapted from Serra-Juhe C and Tizzano EF, 201919

Your early action could limit the irreversible damage associated with
SMA4,5,10,29

References

NMD, Neuromuscular disease.

REFERENCES

* 1. Kolb SJ and Kissel JT. Neurol Clin. 2015;33(4):831–46.
* 2. Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy. 2000 Feb 24
[Updated 2019 Nov 14]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors.
GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle;
1993–2020.
* 3. Wang CH, et al. J Child Neurol. 2007;22(8):1027–49.
* 4. Govoni A, et al. Mol Neurobiol. 2018;55(8):6307–18.
* 5. Glascock J, et al. J Neuromuscul Dis. 2018;5(2):145–58.
* 6. Verhaart IEC, et al. Orphanet J Rare Dis. 2017;12:124.
* 7. Richter T, et al. Value Health. 2015;18(6):906–14.
* 8. Mercuri E, et al. Neurology. 2019;93(13):e1241–7.
* 9. Mercuri E, et al. Orphanet J Rare Dis. 2020;15(1):84.
* 10. Schorling DC, et al. J Neuromuscl Dis. 2020;7:1–13.
* 11. D’Amico A, et al. Orphanet J Rare Dis. 2011;6:71.
* 12. Cure SMA (2023). About SMA. Available at: https://www.curesma.org/about/.
Date accessed: November 2023.
* 13. Verhaart IEC, et al. Additional file 2: Table S1. Overview carrier
frequencies of SMA. Supplementary material to Verhaart IEC, et al. Orphanet J
Rare Dis. 2017;12:124. Available at:
https://ojrd.biomedcentral.com/articles/10.1186/s13023-017-0671-8. Date
accessed: November 2023.
* 14. Coovert DD, et al. Hum Mol Genet. 1997;6(8):1205–14.
* 15. Anderton RS and Mastaglia FL. Expert Rev Neurother. 2015;15(8):895–908.
* 16. Lefebvre S, et al. Cell. 1995;80:155–65.
* 17. National Institute for Health (NIH) (2020a). Genetics home reference.
Your guide to understanding genetic conditions. SMN1 gene. Available at:
https://ghr.nlm.nih.gov/gene/SMN1. Date accessed: November 2023.
* 18. NIH (2020b). Genetics home reference. Your guide to understanding genetic
conditions. SMN2 gene. Available at: https://ghr.nlm.nih.gov/gene/SMN2. Date
accessed: November 2023.
* 19. Serra-Juhe C and Tizzano EF. Eur J Hum Genet. 2019;27(12):1774–82.
* 20. Finkel RS, et al. Neurology. 2014;83(9):810–7.
* 21. Kolb SJ, et al. Ann Neurol. 2017;82(6):883–91.
* 22. Kirschner J, et al. Eur J Paediatr Neurol. 2020;28:38–43. Published
online ahead of print.
* 23. Swoboda KJ, et al. Ann Neurol. 2005;57(5):704–12.
* 24. Finkel RS. Neuromuscul Disord. 2013;23(2):112–5.
* 25. Qian Y, et al. BMC Neurol. 2015;15:217.
* 26. Mammas IN and Spandidos DA. Exp Ther Med. 2018;15:3673–9.
* 27. Lurio JG, et al. Am Fam Physician. 2015;91(1):38–44.
* 28. Waldrop MA and Elsheikh BH. Neurol Clin. 2020;38(3):505–18.
* 29. Lowes LP, et al. Pediatr Neurol. 2019;98:39–45.

GL-UNB-23-0009 V2 | Date of preparation: November 2023

This site is designed to help you learn about the early signs of spinal muscular
atrophy (SMA) and what to do if you spot them

This website is intended for Global Healthcare Professionals only.
Please confirm you are a Healthcare Professional.

I AM A HEALTHCARE PROFESSIONAL

I AM A CAREGIVER (PARENT / GUARDIAN)

You are now leaving the Healthcare Professionals (HCP) website

Stay on HCP website

GO TO CAREGIVER WEBSITE

NOTICE

Novartis Gene Therapies provides links to third-party sites as a convenience and
is not responsible for the content of these sites.

Would you like to proceed? Click “Cancel” to keep browsing signsofsma.com

CANCEL

PROCEED

YOUR PRIVACY IS IMPORTANT FOR US.

We use cookies to enhance your experience when visiting our websites:
performance cookies show us how you use this website, functional cookies
remember your preferences and targeting cookies help us to share content
relevant to you. Select “Accept all” for giving your consent to all cookies,
select “Cookie settings” for managing the different cookies or select “Reject
all” for using only strictly necessary cookies. You can change your cookie
settings at any point of time by pressing the cookie settings link on the
website.
Cookie Settings Reject all Accept all

COOKIE PREFERENCE CENTER

When you visit any website, it may store or retrieve information on your browser
by using cookies. The cookies are set to expire when the information is no
longer needed or after a maximum period of 13 months. You can choose to allow or
not to allow some specific types of cookies. Click on the different category
headings below to find out more. Please note that blocking some types of cookies
may impact your experience on the site and the services we are able to offer.
Accept all

MANAGE CONSENT PREFERENCES

STRICTLY NECESSARY COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms. You can set your browser to block
or alert you about these cookies, but some parts of the site will not then work.
These cookies do not store any personally identifiable information.

Cookies Details‎

PERFORMANCE COOKIES

Performance cookies

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site. All
information these cookies collect is aggregated and therefore anonymous. If you
do not allow these cookies we will not know when you have visited our site, and
will not be able to monitor its performance.

Cookies Details‎

TARGETING COOKIES

Targeting cookies

These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant adverts on other sites. They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.

Cookies Details‎
Back Button

COOKIE LIST

Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Save choices

www.signsofsma.com Open in urlscan Pro 52.17.126.66 Public Scan

Form analysis 0 forms found in the DOM

Text Content

www.signsofsma.com Open in urlscan Pro
52.17.126.66 Public Scan

Form analysis
0 forms found in the DOM